Think of Sulfonylureas as CV Neutral
New evidence will provide more reassurance about the cardiovascular safety of sulfonylureas (glimepiride, etc) for type 2 diabetes.
There's been debate for years over whether sulfonylureas increase CV risk...mainly due to data with the old, first-generation tolbutamide.
To date, all sulfonylurea med labels warn of increased CV mortality.
Get unlimited access through an Enterprise license
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 300+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Not sold to individuals